CBF‐AML patients who are unable to complete all planned consolidation therapy or have persistent disease specific transcripts detectable at low levels via qRTPCR benefit from DAC maintenance in terms of long mRFS and salvage treatment free remission or death. Here, CEBPZ is linked to acute myeloid leukemia.